Safety, Tolerability, and Pharmacokinetics of BHV-2100, a First-in-class TRPM3 Antagonist for Pain and Migraine (S11.004)
Christopher Jensen, Irfan Qureshi, Joris Vriens, Andrew T. Lucas et al.
Citations
1 citations
Journal
Neurology
Topics
Migraine and Headache Studies
Field-Weighted Citation Impact (FWCI)
1.47
article
Safety, Tolerability, and Pharmacokinetics of BHV-2100, a First-in-class TRPM3 Antagonist for Pain and Migraine (S11.004)
Christopher Jensen, Irfan Qureshi, Joris Vriens, Andrew T. Lucas, Richard Bertz, Thomas Voets, Mary Donohue, Patricia K. Mydlow, Beth Emerson, Vladimir Coric, Eric Ashbrenner, Volkan Granit
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
NeurologyVol. 104(7_Supplement_1)
Institutions
Ludlow Community Hospital (GB), Biohaven Pharmaceuticals (United States) (US), VIB-KU Leuven Center for Brain & Disease Research (BE), KU Leuven (BE)